CCA
IMNM icon

Cygnus Capital Advisors’s Immunome IMNM Stock Holding History

Cygnus Capital Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,880
Closed -$150K – 85
2026
Q1 		$150K Sell
6,880
-1,105
-14% -$24.6K 0.1% 55
2025
Q4 		$172K Buy
+7,985
New +$140K 0.13% 52

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Cygnus Capital Advisors's IMNM Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Immunome (IMNM) in Q2 2026, closing a stake of 6,880 shares — an estimated $150K sold.

Cygnus Capital Advisors first reported a position in IMNM in Q4 2025 and held it in 2 quarters. The position peaked at $172K in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 6,880 Immunome shares in Q2 2026, an estimated $150K.
  • Cygnus Capital Advisors first reported a position in Immunome in Q4 2025 and held it in 2 quarters.
  • Cygnus Capital Advisors's Immunome position peaked at $172K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.